ClinicalTrials.gg
RecruitingNCT07622017K-BOOSTUpdated Nov 16, 2026

KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer

A Phase 2 interventional study of KRC-01 (KORTUC) and Radiotherapy in Rectal Cancer, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 16, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 160 studies in Rectal Neoplasms with a site in France — 28 open to participants now, 40 under way, 6 of them phase 3. Rectal Neoplasms · France.

Planned enrollment
102nd of 120
24 · median 109
Started
2026
with 6 others
Phase 2
45 of 160
2 open now
Primary completion
2029-01
later than 27 of 39 live
Registered
158th of 160
by date
Lead sponsor
5 of 160
Gustave Roussy, Cancer Campus, Grand Paris

Among the 160 studies in Rectal Neoplasms with a site in France, this one is the 102nd largest by planned enrollment of the 120 interventional ones that give a count, is one of 7 that started in 2026, is one of 45 in phase 2, reaches primary completion later than 27 of the 39 other live ones, and was the 158th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

28 of the 160 studies in Rectal Neoplasms with a site in France are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Rectal Neoplasms with a site in France, or all of them as a file.
02

Study summary

This phase II clinical trial is evaluating whether adding KRC-01 injections to standard chemoradiotherapy may improve treatment outcomes in patients with locally advanced rectal cancer without metastases.

KRC-01 is an investigational product designed to improve the effectiveness of radiotherapy by increasing oxygen levels inside tumors, which may help radiation work better. KRC-01 contains hydrogen peroxide and sodium hyaluronate and is injected directly into the tumor before radiotherapy sessions.

Previous clinical experience in Japan, including studies in several types of cancer, suggested that this approach may improve tumor oxygenation and enhance the effect of radiotherapy.

The main objective of the K-BOOST study is to evaluate how many patients achieve a complete clinical response after treatment with chemoradiotherapy combined with intratumoral KRC-01 injections, potentially allowing some patients to avoid surgery. Surgery may still be recommended depending on the individual response to treatment.

Approximately 24 patients will participate in this multicenter French study. The experimental treatment period lasts approximately 26 weeks, and participants will be followed for up to 2 years.

03

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • Intratumoral
  • chemoradiotherapy
  • advanced rectal cancer
  • Organ Preservation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females ≥ 18 years of age.
  2. (ECOG) performance status 0 or 1.
  3. Histopathologically confirmed locally advanced rectal adenocarcinoma, stage III (high risk)
  4. No evidence of disease on computed tomography (chest and abdomen), including resectable metastases. (M0, and no oligometastases)
  5. At least one of the following criteria: cT4a, cT4b, presence of extramural invasion (EMVI+), cN2, involvement of the mesorectal fascia (MFI+), involvement of lateral lymph nodes (lat LN+)
  6. Adenocarcinoma located with a lower border less than 15 cm from the anal margin
  7. Primary resection without chemoradiotherapy is unlikely to achieve clear margins.
  8. Tumor lesion must be mesurable by endoscopic visual assessment
  9. Target tumor is accessible for intratumoral injections.
  10. Intention to undergo treatment including 5 Fu based chemoradiotherapy and CAPOX (6 cycles) or FOLFOX (9 cycles)
  11. > 6 months
  12. Acceptable organ functions, as evidenced by the following laboratory data:

    1. (AST) and alanine aminotransferase (ALT) ≤2.0× (ULN).
    2. Total serum ≤ 1.5×ULN.
    3. (ANC): ≥ 1500 cells/mm³.
    4. count: ≥ 100,000 cells/mm³.
    5. : ≥ 9.0 g/dL.
    6. Serum creatinine levels ≤ 1.5×ULN, or calculated (by formula or other accepted formula) and measured creatinine clearance ≥50 mL/min.
    7. Amylase and lipase ≤ 1.5xULN.
    8. Adequate blood coagulation function as evidenced by an (INR) ≤ 1.5.
  13. Women of must have a negative serum β-HCG pregnancy test within 7 days prior to the administration of the first study treatment and/or urine pregnancy 12 hours prior to the administration of the first study treatment.

    1. Female subjects of childbearing potential should be willing to use a highly effective method of or be surgically sterile or abstain from heterosexual activity during the study treatment and for at least 15 months after the last dose of oxaliplatin and 6 months after the last dose of capecitabine or 5-fluorouracil, whichever period is longer.. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year. cf. section 7.8 "Pregnancy and contraception") Note: A woman is considered of childbearing potential following menarche and until becoming (≥ 12 months of non-therapy-induced amenorrhea) unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral oophorectomy, and bilateral salpingectomy. A "highly effective" birth control method is one which can achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include: combined (estrogen and progestogen containing) hormonal contraception; progestogen-only hormonal contraception associated with inhibition of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner (on the understanding that this is the only partner during the whole study duration), and sexual abstinence during the entire period of risk associated with study treatment. To prevent the risk of interaction between the study drug and hormonal contraceptives, hormonal contraceptives should be supplemented with a barrier method (preferably male condom). Following methods are considered as unacceptable methods (non-exhaustive list): periodic abstinence (calendar, symptothermal, post-ovulation methods) and withdrawal (coitus interruptus).
    2. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy until at least 12 months after the last dose of oxaliplatin and 3 months after the last dose of capecitabine or 5-fluorouracil, whichever period is longer.

    Also, it is recommended that women of childbearing potential partner use a highly effective method of contraception.

  14. Patients who either do not consent to a tumor or do not have accessible lesions will not be eligible.
  15. Patients should understand, sign, and date the written form prior to any protocol-specific procedures performed.
  16. Patient should be able and willing to comply with study visits and procedures as per protocol.
  17. Patient must be affiliated to a social security system or beneficiary of the same.

Exclusion criteria

Exclusion Criteria:

  1. Patients not deemed fit for radiotherapy or preexisting condition which would deter radiotherapy, e.g., fistulas, severe ulcerative colitis (including subjects currently taking sulphasalazine), active Crohn's disease, prior adhesions.
  2. Patients with hypokalemia below the lower limit of normal, hypomagnesemia, hypocalcemia, or /QTc interval >450 msec in males or >470 msec in females at inclusion are not eligible.
  3. Any Previous radiotherapy in the pelvic region.
  4. to MRI (e.g., subjects with pacemakers, claustrophobia, excessive weight, etc.).
  5. Participation in another clinical study with an product during the last 3 months.
  6. Prior rectal surgery.
  7. Prior investigational treatment for rectal cancer.
  8. Patients with known high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) tumors are not eligible, as these patients may benefit from standard-of-care immunotherapy.
  9. High medical risk because of systemic diseases (e.g., uncontrolled infections, uncontrolled diabetes) in addition to the qualifying disease under study. Patients must not have any uncontrolled concurrent illness including, but not limited to, severe active or uncontrolled infection, symptomatic congestive heart failure, unstable, angina pectoris, cardiac arrhythmia, uncontrolled diabetes mellitus or psychiatric illness/social situations that would limit compliance with study requirements.
  10. Patients receiving therapeutic anticoagulation are not eligible. Prophylactic anticoagulation at low dose (e.g., thromboprophylaxis) may be allowed at the investigator's discretion, provided that the bleeding risk is considered minimal.
  11. Patients receiving concomitant treatment with brivudine or who have received brivudine within the previous 4 weeks.
  12. Peripheral sensory neuropathy grade ≥2 (for the future administration of oxaliplatin)
  13. Dihydropyrimidine deshydrogenase (DPD) deficiency. DPD status must be assessed prior to inclusion, and uracilemia testing is mandatory before initiation of fluorouracil-based treatment. Patients with unknown DPD status are not eligible.
  14. Concomitant medications/comorbidities that may prevent the patient from receiving study treatments,
  15. Contraindication to fluoropyrimidines or oxaliplatin and capecitabin as mentioned in the SMPC of investigational medicinal products: FOLFOX is contraindicated in patients with known to 5-fluorouracil, oxaliplatin, leucovorin, or other platinum compounds; in those with severe renal impairment ( \<30 mL/min), significant bone marrow suppression, uncontrolled infections, or pre-existing grade ≥2 peripheral neuropathy. It is also contraindicated in individuals with complete or partial dihydropyrimidine dehydrogenase (DPD) deficiency due to the risk of severe 5-FU toxicity, as well as in cases of severe hepatic dysfunction, pregnancy, and breastfeeding. Caution is advised in patients with poor performance status ( ≥3).
  16. Yellow fever vaccine and are contraindicated due to the risk of severe vaccine-induced infection. Note: The currently authorized COVID-19 vaccines are not live vaccines and therefore can be safely administered.
  17. Known history of (HIV) infection or seropositive results consistent with active virus (HBV) or active virus (HCV) infection.
  18. Pregnant or breastfeeding women or intending to become pregnant during the clinical investigation.
  19. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Intratumoral KRC-01 injections combined with standard chemoradiotherapy

    Participants receive intratumoral KRC-01 injections (8 injections) combined with standard long-course chemoradiotherapy (radiotherapy: 50 Gy in 25 fractions plus capecitabine 825 mg/m² orally twice daily for 5 weeks) and consolidation chemotherapy with CAPOX or FOLFOX according to investigator decision and institutional practice. Surgery with total mesorectal excision (TME) may be performed depending on tumor response and multidisciplinary team assessment.

    Drug: KRC-01 (KORTUC) · Radiation: Radiotherapy · Drug: Capecitabine · Drug: CAPOX · Drug: FOLFOX · Procedure: Optionnal TME

Interventions

  • DrugKRC-01 (KORTUC)

    Intratumoral injections administered before radiotherapy.

  • RadiationRadiotherapy

    Standard radiotherapy administered with chemotherapy.

  • Standard chemotherapy regimen (capecitabine) administered with radiotherapy.

  • DrugCAPOX

    Standard chemotherapy regimen (capecitabine and oxaliplatin), after chemoradiotherapy

  • DrugFolfox protocolStudies of Folfox protocolFolfox protocol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Standard chemotherapy regimen (5-fluorouracil, leucovorin, and oxaliplatin), after chemoradiotherapy

  • ProcedureOptionnal TME

    Surgery with total mesorectal excision (TME) may be performed depending on tumor response and multidisciplinary team assessment

06

What researchers measure

Primary outcomes

  1. Clinical Complete Response (cCR) Rate at Week 24

    Clinical complete response (cCR) rate is defined as the proportion of patients with no clinical, rectoscopic, or radiographic evidence of disease at Week 24 after treatment. Patients with at least one missing clinical, rectoscopic, or radiographic evaluation, or lost to follow-up before Week 25, will be considered non-responders.

    Time frame: Week 24

Secondary outcomes

  1. Pathological Complete Response (pCR) Rate

    Pathological complete response (pCR) rate will be assessed in patients undergoing total mesorectal excision (TME) surgery and defined as the proportion of patients with no residual viable tumor identified in the surgical specimen.

    Time frame: At time of surgery (approximately Week 26)

  2. Progression-Free Survival (PFS)

    Progression-free survival (PFS) is defined as the time from study inclusion to disease progression or death from any cause, whichever occurs first.

    Time frame: Up to 24 months

  3. Overall Survival (OS)

    Overall survival (OS) is defined as the time from study inclusion to death from any cause.

    Time frame: Up to 24 months

  4. Incidence of Adverse Events

    Incidence, nature, and severity of adverse events (AEs) will be assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized by system organ class, preferred term, and worst grade experienced

    Time frame: From first study treatment administration up to 24 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jan 2029, 27 months after the start.

Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 27 months is below that.

Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 2, 2026
StartActual
Oct 5, 2026was Jul 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jul 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
Show 2 sites
  • Gustave Roussy · Villejuif, Franceno status→Recruiting
  • Institut Bergonié · Bordeaux, Franceno status→Not yet recruiting
Nov 16, 2026
Start date
Jul 2026→Oct 5, 2026 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
    Show 2 sites
    • Gustave Roussy · Villejuif, Franceno status→Recruiting
    • Institut Bergonié · Bordeaux, Franceno status→Not yet recruiting
    Start date Jul 2026→Oct 5, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07622017
Collaborators
Kortuc, Inc.
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Oct 5, 2026
Primary completion
Jan 2029 (estimated)
Completion
Jul 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Eric Deutsch, MD, PhD
Contact
Eric.DEUTSCH@gustaveroussy.fr
(+33)142116573

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion